Facing Stage 4 with Hope: CRS-HIPEC for Peritoneal Carcinomatosis
A stage 4 cancer diagnosis can feel like a dead end, but there is hope. For certain abdominal cancers that have spread to the peritoneum (lining of the abdomen), a combined surgical approach called Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) offers a chance for long-term survival and even a cure.
What is CRS-HIPEC?
Cytoreductive Surgery (CRS):
This precise and meticulous surgery aims to remove all visible tumors and potentially cancerous tissue from the abdomen achieving a grossly complete cytoreduction.
Hyperthermic Intraperitoneal Chemotherapy (HIPEC):
After CRS, chemotherapy drugs are circulated and perfused throughout the abdominal cavity in a peritoneal dialysis fluid at a high temperature of 40-42 degree Celsius to target microscopic cancer cells.
Data and Facts about CRS-HIPEC:
Improved Survival:
Studies show CRS-HIPEC can significantly improve survival rates compared to traditional chemotherapy alone. For example, one study found a median overall survival of 67 months for stage 3 ovarian cancer patients treated with CRS-HIPEC compared to 39 months with chemotherapy.
Curative Potential:
CRS-HIPEC offers the potential for a cure in some cancers, particularly pseudomyxoma peritonei (appendiceal and ovarian origin) and certain types of ovarian cancer.
Multidisciplinary Approach:
The success of CRS-HIPEC relies on a skilled team of surgeons, medical oncologists, anesthesiologists, ICU and critical care specialists and specialized nurses working together.
Not for Everyone:
CRS-HIPEC is a complex surgery with potential complications like bleeding, infection, bowel issues and, a longer recovery period requiring prolonged ICU or hospital stay. Careful patient selection and thorough pre-operative evaluation are crucial.
Here’s a table summarizing the types of cancers that can benefit from CRS-HIPEC:
Cancer Type | Potential Benefit |
Pseudomyxoma Peritonei (Appendiceal or ovarian origin) | High chance of cure |
Improved survival and potential cure in some cases | |
Colorectal Cancer (Peritoneal Carcinomatosis) | Improved survival |
Gastric Cancer (Peritoneal Carcinomatosis) | Improved survival |
Mesothelioma | Improved survival |
If you have been diagnosed with stage 4 abdominal cancer, discuss CRS-HIPEC with your doctor to see if it’s a potential treatment option for you. Early evaluation and a multidisciplinary approach are key to optimizing outcomes.
Important Disclaimer:
This blog is for informational purposes only and should not be considered medical advice. Always consult with your doctor to discuss the best course of treatment for your individual case.